GW’s Cannabidiol Drug To Be Funded In England For Epilepsy
More Data To Be Provided On Benefits And Safety
Executive Summary
GW Pharma’s cannabidiol drug Epidyolex can be funded on the NHS in England for seizures in patients with Dravet syndrome or Lennox-Gastaut syndrome. The company will have to provide additional data to address a number of uncertainties, including the waning of treatment effect, while more safety data are expected from an ongoing study.
You may also be interested in...
England’s NICE Backs Epidyolex For Seizures, Sativex For MS Spasticity
Health technology assessment body NICE has given the thumbs-up to Epidyolex and Sativex, which become the first plant-derived medicinal cannabis products to secure routine NHS funding. It has also issued positive guidance on other products including nabilone, but turned down the use of cannabis-based drugs in chronic pain.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.